000916865 001__ 916865
000916865 005__ 20231027114351.0
000916865 0247_ $$2doi$$a10.1002/alz.12696
000916865 0247_ $$2ISSN$$a1552-5260
000916865 0247_ $$2ISSN$$a1552-5279
000916865 0247_ $$2Handle$$a2128/34203
000916865 0247_ $$2pmid$$a35715930
000916865 0247_ $$2WOS$$aWOS:000812481000001
000916865 037__ $$aFZJ-2023-00157
000916865 082__ $$a610
000916865 1001_ $$0P:(DE-HGF)0$$aAltomare, Daniele$$b0$$eCorresponding author
000916865 245__ $$aDescription of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
000916865 260__ $$aHoboken, NJ$$bWiley$$c2023
000916865 3367_ $$2DRIVER$$aarticle
000916865 3367_ $$2DataCite$$aOutput Types/Journal article
000916865 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1679986881_26965
000916865 3367_ $$2BibTeX$$aARTICLE
000916865 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000916865 3367_ $$00$$2EndNote$$aJournal Article
000916865 520__ $$aIntroduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.Keywords: Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline.
000916865 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000916865 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x1
000916865 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000916865 7001_ $$0P:(DE-HGF)0$$aCollij, Lyduine$$b1
000916865 7001_ $$0P:(DE-HGF)0$$aCaprioglio, Camilla$$b2
000916865 7001_ $$0P:(DE-HGF)0$$aScheltens, Philip$$b3
000916865 7001_ $$0P:(DE-HGF)0$$avan Berckel, Bart N. M.$$b4
000916865 7001_ $$0P:(DE-HGF)0$$aAlves, Isadora Lopes$$b5
000916865 7001_ $$0P:(DE-HGF)0$$aBerkhof, Johannes$$b6
000916865 7001_ $$0P:(DE-HGF)0$$ade Gier, Yvonne$$b7
000916865 7001_ $$0P:(DE-HGF)0$$aGaribotto, Valentina$$b8
000916865 7001_ $$0P:(DE-HGF)0$$aMoro, Christian$$b9
000916865 7001_ $$0P:(DE-HGF)0$$aPoitrine, Léa$$b10
000916865 7001_ $$0P:(DE-HGF)0$$aDelrieu, Julien$$b11
000916865 7001_ $$0P:(DE-HGF)0$$aPayoux, Pierre$$b12
000916865 7001_ $$0P:(DE-HGF)0$$aSaint-Aubert, Laure$$b13
000916865 7001_ $$0P:(DE-HGF)0$$aMolinuevo, José Luis$$b14
000916865 7001_ $$0P:(DE-HGF)0$$aGrau-Rivera, Oriol$$b15
000916865 7001_ $$0P:(DE-HGF)0$$aGispert, Juan-Domingo$$b16
000916865 7001_ $$0P:(DE-HGF)0$$aMinguillón, Carolina$$b17
000916865 7001_ $$0P:(DE-HGF)0$$aFauria, Karine$$b18
000916865 7001_ $$0P:(DE-HGF)0$$aSanchez, Marta Felez$$b19
000916865 7001_ $$0P:(DE-HGF)0$$aRădoi, Andreea$$b20
000916865 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b21
000916865 7001_ $$0P:(DE-HGF)0$$aJessen, Frank$$b22
000916865 7001_ $$0P:(DE-HGF)0$$aEscher, Claus$$b23
000916865 7001_ $$0P:(DE-HGF)0$$aZeyen, Philip$$b24
000916865 7001_ $$0P:(DE-HGF)0$$aNordberg, Agneta$$b25
000916865 7001_ $$0P:(DE-HGF)0$$aSavitcheva, Irina$$b26
000916865 7001_ $$0P:(DE-HGF)0$$aJelic, Vesna$$b27
000916865 7001_ $$0P:(DE-HGF)0$$aWalker, Zuzana$$b28
000916865 7001_ $$0P:(DE-HGF)0$$aLee, Ho-Yun$$b29
000916865 7001_ $$0P:(DE-HGF)0$$aLee, Lean$$b30
000916865 7001_ $$0P:(DE-HGF)0$$aDemonet, Jean-François$$b31
000916865 7001_ $$0P:(DE-HGF)0$$aPlaza Wuthrich, Sonia$$b32
000916865 7001_ $$0P:(DE-HGF)0$$aGismondi, Rossella$$b33
000916865 7001_ $$0P:(DE-HGF)0$$aFarrar, Gill$$b34
000916865 7001_ $$0P:(DE-HGF)0$$aBarkhof, Frederik$$b35
000916865 7001_ $$0P:(DE-HGF)0$$aStephens, Andrew W.$$b36
000916865 7001_ $$0P:(DE-HGF)0$$aFrisoni, Giovanni B.$$b37
000916865 7001_ $$0P:(DE-HGF)0$$aConsortium, AMYPAD$$b38
000916865 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.12696$$gp. alz.12696$$n3$$p844-856$$tAlzheimer's and dementia$$v19$$x1552-5260$$y2023
000916865 8564_ $$uhttps://juser.fz-juelich.de/record/916865/files/Alzheimer%20s%20Dementia%20-%202022%20-%20Altomare%20-%20Description%20of%20a%20European%20memory%20clinic%20cohort%20undergoing%20amyloid%E2%80%90PET%20The.pdf$$yOpenAccess
000916865 909CO $$ooai:juser.fz-juelich.de:916865$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000916865 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b21$$kFZJ
000916865 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000916865 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
000916865 9141_ $$y2023
000916865 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000916865 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000916865 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-11$$wger
000916865 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000916865 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000916865 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000916865 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000916865 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000916865 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000916865 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000916865 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000916865 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000916865 920__ $$lyes
000916865 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000916865 980__ $$ajournal
000916865 980__ $$aVDB
000916865 980__ $$aUNRESTRICTED
000916865 980__ $$aI:(DE-Juel1)INM-2-20090406
000916865 9801_ $$aFullTexts